International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis

An international consensus on antineutrophil cytoplasm antibodies (ANCA) testing in eosinophilicgranulomatosiswithpolyangiitis(EGPA) ispresented.ANCA,speci fi cformyeloperoxidase(MPO),canbedetected in 30 – 35% of patients with EGPA. MPO-ANCA should be tested with antigen-speci fi c immunoassays in any patient with eosinophilic asthma and clinical features suggesting EGPA, including constitutional symptoms; purpura; polyneuropathy; unexplained heart, gastrointestinal, orkidneydisease;and/orpulmonaryin fi ltratesorhemorrhage.Apositive MPO-ANCA result contributes to the diagnostic workup for EGPA.

[1]  S. Vermeire,et al.  2020 international consensus on ANCA testing beyond systemic vasculitis. , 2020, Autoimmunity reviews.

[2]  G. Sobue,et al.  Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA , 2020, Neurology.

[3]  U. Specks,et al.  Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab , 2020, Clinical Rheumatology.

[4]  A. Nanzer,et al.  Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis , 2020, ERJ Open Research.

[5]  D. Cornec,et al.  Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease , 2019, Expert review of clinical immunology.

[6]  William J. Astle,et al.  Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status , 2019, Nature Communications.

[7]  M. Nichelatti,et al.  Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients , 2019, International Archives of Allergy and Immunology.

[8]  D. Jayne,et al.  Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.

[9]  S. Yancey,et al.  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. , 2019, The Journal of allergy and clinical immunology.

[10]  Quanzhen Li,et al.  Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody‐Negative Eosinophilic Granulomatosis with Polyangiitis , 2019, American journal of respiratory and critical care medicine.

[11]  J. Damoiseaux,et al.  Detection of Anti-neutrophil Cytoplasmic Antibodies (ANCA) by Indirect Immunofluorescence. , 2018, Methods in molecular biology.

[12]  Welfare for Intractable Vasculitis.  Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. , 2018 .

[13]  T. Sugiyama,et al.  Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis , 2018, The Journal of Rheumatology.

[14]  C. Kallenberg,et al.  Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis , 2017 .

[15]  A. Vaglio,et al.  Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.

[16]  T. Tsuburai,et al.  Longterm Prognosis of 121 Patients with Eosinophilic Granulomatosis with Polyangiitis in Japan , 2017, The Journal of Rheumatology.

[17]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[18]  P. van Paassen,et al.  Maintaining remission in patients with granulomatosis with polyangiitis or microscopic polyangiitis: the role of ANCA , 2017 .

[19]  A. Ishizu,et al.  The Presence of Anti-Lactoferrin Antibodies in a Subgroup of Eosinophilic Granulomatosis with Polyangiitis Patients and Their Possible Contribution to Enhancement of Neutrophil Extracellular Trap Formation , 2016, Front. Immunol..

[20]  S. Moiseev,et al.  Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis , 2016, The Journal of Rheumatology.

[21]  P. van Paassen,et al.  Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays , 2016, Annals of the rheumatic diseases.

[22]  P. van Paassen,et al.  Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). , 2016, Autoimmunity reviews.

[23]  D. Schroeder,et al.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 , 2016, Arthritis & rheumatology.

[24]  P. Merkel,et al.  EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis , 2016, Annals of the rheumatic diseases.

[25]  Jun Zhang,et al.  Anti-neutrophil cytoplasmic antibodies in cholesterol embolism: A case report and literature review , 2016, Experimental and therapeutic medicine.

[26]  L. Mouthon,et al.  Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangitis. , 2016, Autoimmunity reviews.

[27]  S. Heymans,et al.  Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. , 2015, International journal of cardiology.

[28]  M. Ando,et al.  Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse , 2015, The Journal of Rheumatology.

[29]  M. Humbert,et al.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. , 2015, European journal of internal medicine.

[30]  O. Vignaux,et al.  Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. , 2015, Autoimmunity reviews.

[31]  J. Ninet,et al.  Long‐Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss) , 2015, Arthritis care & research.

[32]  P. Merkel,et al.  Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) , 2015, PloS one.

[33]  P. van Paassen,et al.  ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. , 2015, Journal of the American Society of Nephrology : JASN.

[34]  P. Merkel,et al.  Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.

[35]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[36]  R. Uehara,et al.  A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan , 2014, Modern rheumatology.

[37]  S. Nishio,et al.  Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. , 2014, Journal of the American Society of Nephrology : JASN.

[38]  S. Moiseev,et al.  Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg–Strauss; EGPA): to use or not to use? , 2013, Annals of the rheumatic diseases.

[39]  L. Mouthon,et al.  Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. , 2013, Journal of autoimmunity.

[40]  W. Szczeklik,et al.  ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center. , 2013, Clinical and experimental rheumatology.

[41]  F. Moosig,et al.  Getting rid of MPO-ANCA: a matter of disease subtype. , 2013, Rheumatology.

[42]  S. Bibby,et al.  Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. , 2013, The Journal of allergy and clinical immunology.

[43]  M. Colombo,et al.  Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. , 2012, Blood.

[44]  F. Moosig,et al.  A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients , 2012, Annals of the rheumatic diseases.

[45]  A. Vaglio,et al.  IgG4 immune response in Churg–Strauss syndrome , 2011, Annals of the rheumatic diseases.

[46]  H. Tilg,et al.  Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. , 2011, Rheumatology.

[47]  S. Bombardieri,et al.  [Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre]. , 2011, Reumatismo.

[48]  C. Kallenberg,et al.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.

[49]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[50]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[51]  S. Heymans,et al.  Cardiac involvement in Churg-Strauss syndrome. , 2010, Arthritis and rheumatism.

[52]  W. Kaiser,et al.  Cardiac Involvement in Churg-Strauss Syndrome: Impact of Endomyocarditis , 2009, Medicine.

[53]  A. Salama,et al.  Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. , 2008, Rheumatology.

[54]  C. Ribi,et al.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. , 2008, Arthritis and rheumatism.

[55]  L. Mouthon,et al.  Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. , 2007, Arthritis and rheumatism.

[56]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[57]  Laura Pavone,et al.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.

[58]  U. Specks,et al.  Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. , 2003, The American journal of medicine.

[59]  S. van der Linden,et al.  An unusual case of ANCA positive disease , 2003, Annals of the rheumatic diseases.

[60]  P. Heeringa,et al.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. , 2002, The Journal of clinical investigation.

[61]  C. Kallenberg,et al.  Antimyeloperoxidase-associated lung disease. An experimental model. , 1999, American journal of respiratory and critical care medicine.

[62]  C. Kallenberg,et al.  Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. , 1991, The American journal of medicine.

[63]  R. Goldschmeding,et al.  Antimyeloperoxidase antibodies in the Churg-Strauss syndrome , 1991, Thorax.

[64]  J. Elema,et al.  Clinical and histopathological association of 29kD‐ANCA and MPO‐ANCA , 1990, APMIS. Supplementum.

[65]  D. Harrison,et al.  Antibodies to neutrophil cytoplasmic antigens in Wegener's granulomatosis and other conditions. , 1989, Thorax.

[66]  G. Hughes,et al.  Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg‐Strauss Syndrome , 1984, Medicine.

[67]  M. Humbert,et al.  Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis , 2017, Autoimmunity reviews.

[68]  S. Moiseev,et al.  Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. , 2016, Joint, bone, spine : revue du rhumatisme.

[69]  D. Blockmans,et al.  There is no benefit in routinely monitoring ANCA titres in patients with granulomatosis with polyangiitis. , 2015, Clinical and experimental rheumatology.

[70]  L. Mouthon,et al.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. , 2013, Arthritis and rheumatism.

[71]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[72]  P. Seo.  Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis , 2010 .

[73]  L. Mouthon,et al.  Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. , 2005, Annals of internal medicine.

[74]  L. Guillevin,et al.  Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. , 1999, Medicine.

[75]  Markus Voelter,et al.  State of the Art , 1997, Pediatric Research.